ID   IRAK3_HUMAN             Reviewed;         596 AA.
AC   Q9Y616; B4DQ57;
DT   09-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   08-FEB-2011, sequence version 2.
DT   10-MAY-2017, entry version 149.
DE   RecName: Full=Interleukin-1 receptor-associated kinase 3;
DE            Short=IRAK-3;
DE            EC=2.7.11.1;
DE   AltName: Full=IL-1 receptor-associated kinase M;
DE            Short=IRAK-M;
GN   Name=IRAK3 {ECO:0000312|EMBL:AAH57800.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAD40879.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, COFACTOR, TISSUE
RP   SPECIFICITY, AND VARIANT VAL-147.
RC   TISSUE=Peripheral blood lymphocyte;
RX   PubMed=10383454; DOI=10.1074/jbc.274.27.19403;
RA   Wesche H., Gao X., Li X., Kirschning C.J., Stark G.R., Cao Z.;
RT   "IRAK-M is a novel member of the Pelle/interleukin-1 receptor-
RT   associated kinase (IRAK) family.";
RL   J. Biol. Chem. 274:19403-19410(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   VAL-147.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4] {ECO:0000312|EMBL:AAH57800.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   VAL-147.
RC   TISSUE=Placenta {ECO:0000312|EMBL:AAH57800.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INVOLVEMENT IN ASRT5, AND VARIANTS LEU-22; ALA-111; MET-134; VAL-400
RP   AND GLN-429.
RX   PubMed=17503328; DOI=10.1086/518259;
RA   Balaci L., Spada M.C., Olla N., Sole G., Loddo L., Anedda F.,
RA   Naitza S., Zuncheddu M.A., Maschio A., Altea D., Uda M., Pilia S.,
RA   Sanna S., Masala M., Crisponi L., Fattori M., Devoto M.,
RA   Doratiotto S., Rassu S., Mereu S., Giua E., Cadeddu N.G., Atzeni R.,
RA   Pelosi U., Corrias A., Perra R., Torrazza P.L., Pirina P., Ginesu F.,
RA   Marcias S., Schintu M.G., Del Giacco G.S., Manconi P.E., Malerba G.,
RA   Bisognin A., Trabetti E., Boner A., Pescollderungg L., Pignatti P.F.,
RA   Schlessinger D., Cao A., Pilia G.;
RT   "IRAK-M is involved in the pathogenesis of early-onset persistent
RT   asthma.";
RL   Am. J. Hum. Genet. 80:1103-1114(2007).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-467, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [7]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-57; SER-84; VAL-147; VAL-171;
RP   LEU-288; GLN-384; THR-391 AND ASN-482.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Inhibits dissociation of IRAK1 and IRAK4 from the Toll-
CC       like receptor signaling complex by either inhibiting the
CC       phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor
CC       complex. {ECO:0000250|UniProtKB:Q8K4B2,
CC       ECO:0000269|PubMed:10383454}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:10383454}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10383454};
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y616-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y616-2; Sequence=VSP_041020;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in peripheral blood
CC       lymphocytes. {ECO:0000269|PubMed:10383454}.
CC   -!- DISEASE: Asthma-related traits 5 (ASRT5) [MIM:611064]: Asthma-
CC       related traits include clinical symptoms of asthma, such as
CC       coughing, wheezing, dyspnea, bronchial hyperresponsiveness as
CC       assessed by methacholine challenge test, serum IgE levels, atopy
CC       and atopic dermatitis. {ECO:0000269|PubMed:17503328}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. Pelle subfamily. {ECO:0000305}.
CC   -!- CAUTION: Ser-293 is present instead of the conserved Asp which is
CC       expected to be an active site residue. Low level
CC       autophosphorylation activity has been reported in PubMed:10383454,
CC       while other authors describe this as an inactive kinase.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF113136; AAD40879.1; -; mRNA.
DR   EMBL; AK298645; BAG60819.1; -; mRNA.
DR   EMBL; AC078889; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC078927; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC057800; AAH57800.1; -; mRNA.
DR   EMBL; BC069388; AAH69388.1; -; mRNA.
DR   CCDS; CCDS44937.1; -. [Q9Y616-2]
DR   CCDS; CCDS8975.1; -. [Q9Y616-1]
DR   RefSeq; NP_001135995.1; NM_001142523.1. [Q9Y616-2]
DR   RefSeq; NP_009130.2; NM_007199.2. [Q9Y616-1]
DR   UniGene; Hs.369265; -.
DR   ProteinModelPortal; Q9Y616; -.
DR   SMR; Q9Y616; -.
DR   BioGrid; 116382; 18.
DR   IntAct; Q9Y616; 17.
DR   MINT; MINT-97148; -.
DR   STRING; 9606.ENSP00000261233; -.
DR   BindingDB; Q9Y616; -.
DR   ChEMBL; CHEMBL5081; -.
DR   GuidetoPHARMACOLOGY; 2044; -.
DR   iPTMnet; Q9Y616; -.
DR   PhosphoSitePlus; Q9Y616; -.
DR   BioMuta; IRAK3; -.
DR   DMDM; 322510038; -.
DR   EPD; Q9Y616; -.
DR   PaxDb; Q9Y616; -.
DR   PeptideAtlas; Q9Y616; -.
DR   PRIDE; Q9Y616; -.
DR   DNASU; 11213; -.
DR   Ensembl; ENST00000261233; ENSP00000261233; ENSG00000090376. [Q9Y616-1]
DR   Ensembl; ENST00000457197; ENSP00000409852; ENSG00000090376. [Q9Y616-2]
DR   GeneID; 11213; -.
DR   KEGG; hsa:11213; -.
DR   UCSC; uc001sth.4; human. [Q9Y616-1]
DR   CTD; 11213; -.
DR   DisGeNET; 11213; -.
DR   GeneCards; IRAK3; -.
DR   GeneCards; MIR6502; -.
DR   HGNC; HGNC:17020; IRAK3.
DR   HPA; HPA043097; -.
DR   MalaCards; IRAK3; -.
DR   MIM; 604459; gene.
DR   MIM; 611064; phenotype.
DR   neXtProt; NX_Q9Y616; -.
DR   OpenTargets; ENSG00000090376; -.
DR   PharmGKB; PA38431; -.
DR   eggNOG; KOG1187; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00530000063073; -.
DR   HOGENOM; HOG000060319; -.
DR   HOVERGEN; HBG052146; -.
DR   InParanoid; Q9Y616; -.
DR   KO; K04732; -.
DR   OMA; KLTDFAM; -.
DR   OrthoDB; EOG091G0YKT; -.
DR   PhylomeDB; Q9Y616; -.
DR   TreeFam; TF328924; -.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-446652; Interleukin-1 signaling.
DR   SignaLink; Q9Y616; -.
DR   SIGNOR; Q9Y616; -.
DR   GeneWiki; IRAK3; -.
DR   GenomeRNAi; 11213; -.
DR   PRO; PR:Q9Y616; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000090376; -.
DR   CleanEx; HS_IRAK3; -.
DR   ExpressionAtlas; Q9Y616; baseline and differential.
DR   Genevisible; Q9Y616; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0001960; P:negative regulation of cytokine-mediated signaling pathway; IC:BHF-UCL.
DR   GO; GO:0045824; P:negative regulation of innate immune response; ISS:BHF-UCL.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IMP:BHF-UCL.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IMP:BHF-UCL.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine production; ISS:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IMP:BHF-UCL.
DR   GO; GO:0043242; P:negative regulation of protein complex disassembly; IMP:BHF-UCL.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IMP:BHF-UCL.
DR   GO; GO:0010933; P:positive regulation of macrophage tolerance induction; ISS:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043244; P:regulation of protein complex disassembly; ISS:UniProtKB.
DR   GO; GO:0043330; P:response to exogenous dsRNA; ISS:BHF-UCL.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISS:BHF-UCL.
DR   GO; GO:0032494; P:response to peptidoglycan; ISS:BHF-UCL.
DR   GO; GO:0009615; P:response to virus; IC:BHF-UCL.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR033610; IRAK3.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   PANTHER; PTHR24419:SF24; PTHR24419:SF24; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00005; DEATH; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Asthma; ATP-binding; Complete proteome; Kinase;
KW   Magnesium; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    596       Interleukin-1 receptor-associated kinase
FT                                3.
FT                                /FTId=PRO_0000086033.
FT   DOMAIN       41    106       Death. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00064}.
FT   DOMAIN      165    452       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     171    179       ATP. {ECO:0000250|UniProtKB:P51617,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   NP_BIND     295    298       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     192    192       ATP. {ECO:0000250|UniProtKB:P51617,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   BINDING     311    311       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     467    467       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   VAR_SEQ      45    105       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041020.
FT   VARIANT      22     22       P -> L (may be associated with ASRT5;
FT                                dbSNP:rs536546109).
FT                                {ECO:0000269|PubMed:17503328}.
FT                                /FTId=VAR_035212.
FT   VARIANT      57     57       H -> R (in dbSNP:rs35239505).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040581.
FT   VARIANT      84     84       G -> S (in dbSNP:rs34443407).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040582.
FT   VARIANT     111    111       P -> A (may be associated with ASRT5;
FT                                dbSNP:rs373806603).
FT                                {ECO:0000269|PubMed:17503328}.
FT                                /FTId=VAR_035213.
FT   VARIANT     134    134       V -> M (may be associated with ASRT5;
FT                                dbSNP:rs138559915).
FT                                {ECO:0000269|PubMed:17503328}.
FT                                /FTId=VAR_035214.
FT   VARIANT     147    147       I -> V (in dbSNP:rs1152888).
FT                                {ECO:0000269|PubMed:10383454,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_019812.
FT   VARIANT     171    171       I -> V (in dbSNP:rs34682166).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040583.
FT   VARIANT     269    269       G -> S (in dbSNP:rs35823766).
FT                                /FTId=VAR_033901.
FT   VARIANT     270    270       I -> V (in dbSNP:rs11465972).
FT                                /FTId=VAR_031077.
FT   VARIANT     288    288       S -> L (in dbSNP:rs35574245).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040584.
FT   VARIANT     384    384       R -> Q (in dbSNP:rs34272472).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040585.
FT   VARIANT     391    391       M -> T (in dbSNP:rs35737689).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040586.
FT   VARIANT     400    400       L -> V (may be associated with ASRT5;
FT                                dbSNP:rs146120640).
FT                                {ECO:0000269|PubMed:17503328}.
FT                                /FTId=VAR_035215.
FT   VARIANT     429    429       R -> Q (may be associated with ASRT5;
FT                                dbSNP:rs140671957).
FT                                {ECO:0000269|PubMed:17503328}.
FT                                /FTId=VAR_035216.
FT   VARIANT     482    482       D -> N (in dbSNP:rs35756811).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040587.
FT   CONFLICT    560    560       N -> D (in Ref. 2; BAG60819).
FT                                {ECO:0000305}.
SQ   SEQUENCE   596 AA;  67767 MW;  D050150B7BDA5B9A CRC64;
     MAGNCGARGA LSAHTLLFDL PPALLGELCA VLDSCDGALG WRGLAERLSS SWLDVRHIEK
     YVDQGKSGTR ELLWSWAQKN KTIGDLLQVL QEMGHRRAIH LITNYGAVLS PSEKSYQEGG
     FPNILFKETA NVTVDNVLIP EHNEKGILLK SSISFQNIIE GTRNFHKDFL IGEGEIFEVY
     RVEIQNLTYA VKLFKQEKKM QCKKHWKRFL SELEVLLLFH HPNILELAAY FTETEKFCLI
     YPYMRNGTLF DRLQCVGDTA PLPWHIRIGI LIGISKAIHY LHNVQPCSVI CGSISSANIL
     LDDQFQPKLT DFAMAHFRSH LEHQSCTINM TSSSSKHLWY MPEEYIRQGK LSIKTDVYSF
     GIVIMEVLTG CRVVLDDPKH IQLRDLLREL MEKRGLDSCL SFLDKKVPPC PRNFSAKLFC
     LAGRCAATRA KLRPSMDEVL NTLESTQASL YFAEDPPTSL KSFRCPSPLF LENVPSIPVE
     DDESQNNNLL PSDEGLRIDR MTQKTPFECS QSEVMFLSLD KKPESKRNEE ACNMPSSSCE
     ESWFPKYIVP SQDLRPYKVN IDPSSEAPGH SCRSRPVESS CSSKFSWDEY EQYKKE
//
